张伟滨

张伟滨，男，1964年6月生，汉族，研究生，博士，主任医师。民进中央委员、民进上海市委副主委，上海市政协常委，第十四届全国政协委员，上海交通大学医学院附属瑞金医院骨科主任、上海市伤骨科研究所副所长。^[2][3]

小时候，张伟滨因外婆中风未能抢救过来，萌生学医的想法。^[4]后来，张伟滨被上海第二医学院（现为上海交通大学医学院）录取，是中国第一届六年制的医学生。^[4]入职后，张伟滨被分配到了骨科，每三个月一次考试，既有理论知识，也有实践操作。^[4]2025年12月，针对骨肿瘤，张伟滨表示青少年是骨肉瘤的主要群体，他们的人生才刚刚开始，不能让转移成为终结符。^[5]

张伟滨擅长四肢及脊柱骨与软组织肿瘤诊治，尤其是四肢恶性骨肿瘤保肢治疗，转移性骨肿瘤的诊断与治疗。在国际上首创了骨肉瘤肺转移手术联合靶向药物治疗的新模式，主持国家自然科学基金等科研项目多项，以及第一或通讯作者发表论文100余篇。^[6][注1]张伟滨曾获第四届“仁心医者·上海市杰出专科医师奖”。^[6]

小时候，张伟滨因为外婆突然中风晕倒没能抢救过来，埋下学医的种子。^[4]

高考在填报大学志愿的时候，张伟滨把志愿全部都改成了医学院。后来被上海第二医学院（现为上海交通大学医学院）录取，是中国第一届六年制的医学生。^[4]

入职前，张伟滨希望成为普外科医生。在普外科实习时间比较长，手术上手的机会也较多。但被分配到了骨科，那时张伟滨每个月交一次读书笔记，主任认真做点评；每三个月一次考试，既有理论知识，也有实践操作。经历的复杂场面多了，张伟滨的信心也足了。^[4]

2022年7月18日，中国民主促进会上海市第十三次代表大会，民进上海市第十七届委员会第一次全体会议选举张伟滨为民进上海市第十七届委员会副主委。^[1]

张伟滨父亲是大学老师。^[4]

张伟滨主要研究骨肉瘤肺转移作用机理及免疫治疗靶点谱筛选的影响。^[7]张伟滨擅长四肢及脊柱骨与软组织肿瘤诊治，尤其是四肢恶性骨肿瘤保肢治疗，转移性骨肿瘤的诊断与治疗。^[6][注1]

项目编号项目名称课题来源起止年月批准经费承担职责82473015骨肉瘤细胞分泌VCAM1诱导CAFs活化重塑ECM介导肺微转移形成的机制研究国家自然科学基金2025-01~2028-1249万元 课题负责人82141116基于共价键抑制剂库发现骨肉瘤新的靶标蛋白及其生物学功能鉴定国家自然科学基金2022-01~2024-1260万元 课题负责人82072957骨肉瘤干细胞外泌体启动并诱导纤维化特征肺转移前微环境的机制研究国家自然科学基金2021-01~2024-1255万元 课题负责人14JC1492400表面特殊微纳米羟基磷灰石生物学作用机理研究上海市科委重点科技攻关纳米项目2014-09~2017-0840万元 课题负责人81172550阻断 PI3K/mTOR 信号通路诱导分化并靶向治疗骨肉瘤干细胞的分子机制研究国家自然科学基金2012-01~2015-1255万元 课题负责人10431901202重组人MNV-骨形态发生蛋白-2的II期临床研究生物学检测上海市科委科技支撑计划生化重点科技攻关专项2010-09~2013-0934万元 课题负责人08411950600股骨粗隆间骨质疏松性骨折的生物力学评估评价及指导个体最优化内固定应用上海市科委生化重点科技攻关项目2008-09~2011-0925万元 课题负责人

参考资料：^[7]

论文标题期刊 / 会议年份卷期页码Advanced autotuning intensity of NV040208B-CO2-OSU3 on the cGAS/STING axis in osteosarcoma lung metastases.J Immunother Cancer2025S1075-1289(25)00389-5Thioacetamide in Potential POI therapy for Treatment of Osteosarcoma Growth and Metastasis.J Hematol Oncol20255:407591Personalized Neoadjuvant Tumor Organoid-on-a-Chip for Tumor Metastasis and Therapeutic AssessmentAdv Mater202537:121813Driver expanding teratoma among a decade post primary bone arthroplastyJOT202551:142-151Carbon Radicals Potentiate the Efficacy of SpyBase Tumor Vaccines in Osteosarcoma Patients with Pulmonary Metastases.Translational Oncol202445:101909A safe and precise nucleus pulposus cell from induced pluripotent stem cells implemented through POC-1Am J Radiol Oncol202424:38-49Dual RNA-Targeting Sympathetic Nerve Ablation by Cas13d-CasRx Members for Osteosarcoma TreatmentSmall202418(20):2307317Functional response to PD-1 inhibition immunotherapy in advanced metastatic osteosarcoma during long-term disease controlJ Immunother Cancer202412(1):e007051Lenvatinib enhances the autophagosomal gene Beclin 1 and LC3B in vivo metastasis and drug resistance in osteosarcoma.Ann Med2022116:883-895Phosphoproteomic-1 induced programmed cell death 1 mediated immunotherapy by targeting ZSWIM9 in osteosarcomaCancer Sci2022113:4221-4233Renewal of autophagy is associated with concomitant functional recognition after repair in the spared nerve injury modelNeurosci2022103:1821-1830Development and analysis of long noncoding RNA associated osteosarcomaHematol202210:38Upgrading and Validation of a Novel Inflammatory Response Associated Gene Signature to Predict Osteosarcoma Prognosis and Immune Infiltration.J Inflamm Res202215:1271-1279Targeting Achilles heels osteosarcoma induced mitochondrial apoptosis in osteosarcomaCell Death Differ202112:414-419Impaired function outcome of osteosarcoma nerve regeneration is mediated by complex therapy of gene scan analysis and brain functional connectivity of a rat's forebrain nerve repair model.Neural Regen Res202122:8688918ACAN is a Novel Bone Matrix Associated Gene Regulating Osteogenesis, Therapy Resistance and Stem Cell Fate in Soft Tissue SarcomaAm J Cancer Res202111:609Epithelial-to-mesenchymal plastic interconvertible bilayer EscapeCell Tissue Bank202121:424-434Alocasiaodora-205 inhibits immunotherapy by promoting PTEN-mediated PD-L1 upregulation in osteosarcomaAging202012:1142-1151Evaluation of osteosarcoma vaccines with different precipitation-based methods: a retrospective impact on the biomarker analysis for clinical samplesCancer Biomark202029:283-297Establishment and validation of a novel clinical prediction scoring system for osteosarcoma patientsInt J Clin Oncol202025:1089-1098Pre-Osteoclast Regulatory Response Assay by contrast-enhanced MRI: Can We Predict the Progress of Enneking malignant tumors in Patients with Osteosarcoma?J Orthop Res202037:1291-1304Designing Robust Nanocarriers with Controllable Tumor Microenvironment for Cancer TherapyJ Immunother201942:283-294Establishment and characterization of a novel human osteosarcoma cell line from spontaneous pulmonary metastasis in vivoAm Tex Med2019420353-4092024 revision nucleus pulposus transplantation: a guide for data interpretationJ Am Acad Orthop Surg201812(5):313-320Liposomal mPEG-PCL with metabolic intermediates promotes cell migration and invasion by targeting CAAT1Biomed Pharmacother2018103:530-539Renal weight influences bone function in patients with osteosarcoma after the proximal tibia after osteosarcoma reconstruction.Biomed Pharmacother2018103:530-539Metastatic Biology of Osteosarcoma with Circulating DNAKnee201825:303-308Exosomal miR-181a-5p Suppressing Ribosome Biogenesis: Interaction Between Metastasis and Primary Osteosarcoma in a Liquid Biopsy ApproachAm Surg Oncol201826:1842-1851Phosphoproteomic-1 promotes cell migration, invasion and lung metastasis of osteosarcoma through MTA-dependent pathwaysOncologist201722:342-351Antitumor effect of bone sialoprotein kinase inhibitor PRIMA-1 induces apoptosis in osteosarcoma in vitro and in vivoCancer Sci2017108:2441-2451Glycogen synthase kinase-3beta regulates cell migration and collagen production in OSCC via signaling in nucleus pulposus with aging-related disc degeneration.Bosnian J Pathol201744:381-391Effect of reaction energy on local treatment of osteosarcoma in extremity and pelvic: a systematic review and meta-analysisInt J Surg201635:536-543Alginate encapsulated hydroxyapatite microcarriers synthesis, characterization and application evaluationRSC Adv20166:141272-141281Metformin inhibits the proliferation, metastasis, and invasion of human osteosarcoma MG63 cells in vitroTumor Biol201536:11-13cGAS/STING Macrophage Therapy of Osteosarcoma - High-Grade OsteosarcomaSemin Rep20151-13Preliminary study for the use of a new osteosarcoma chemotherapy in the treatment of inducible complications of hemophiliaHaematologica20140:1-4Hydrothermal Preparation and Characterization of Strontium-Substituted Hydroxyapatite Using Acetate as a Homogeneous Precipitation ReagentThe Scientific World Journal2014513-514Reporting the remaining legal right of reaction therapy in osteosarcoma after definitive therapyChin Med J2014128:1621-1629重组腺病毒介导骨桥蛋白反义寡核苷酸对骨肉瘤细胞增殖和侵袭的影响及机制研究中国肿瘤生物治疗201320:761-770All Yu Liu, Jun Ma, Liu Wei, WeiBin Zhang. Synthesis of strontium substituted hydroxyapatite whiskers used as bioceramic mechanical reinforcementMaterials Letters2013103:76-79动力系统理论在骨肉瘤化疗耐药性中的应用及相关分子机制的研究与进展中国组织工程研究201216:743-749Bioinformatics comparison of internal factors in diagnostic musculoskeletal diseases: A Meta-AnalysisJ Saudi Med201210:739-742Sedation modification of biomaterial the effective approach to improve the biological biocompatibility of calcium silicateAdvanced Materials201215:1366-1389The outcome of surgical treatment for recurrent giant cell tumor in the appendicular skeleton: 10-year follow-upJ Orthop Surg201215:64-68人骨肉瘤细胞侵袭转移相关基因的筛选及实验研究上海医学201235:138-144New bone formation in a bone dynamic scaffold loaded with decitabine in the treatment of segmental bone defect: a preliminary studyJ Orthop Sci201217:201-208三维重建和 3D 打印技术辅助治疗小儿骨缺损的初步临床应用中华骨科杂志201131:320-334In vivo evaluation of two types of bioactive scaffold used for tendon-bone interface healing in the reconstruction of anterior cruciate ligamentStem Cells Int201130267-30344Effects of strontium on modified biomaterialsActa Biomater20117:1011-1020Primary clear cell sarcoma of the sacrum: a case reportSarcoma Rev2011402:635-639新辅助化疗对骨肉瘤患者血清学标志物及远期生存率的影响中国组织工程研究2008-康复训练对骨肉瘤患者的疗效及生存质量的影响中国康复刊2008-纳米羟基磷灰石载阿霉素对骨肉瘤 MG-63 细胞增殖的影响上海医学2008-组织工程化骨修复下肢骨缺损的临床应用中国修复重建外科杂志2008-磷酸钙骨水泥在儿童骨缺损的修复应用中国修复重建外科杂志2007-去甲斑蝥素对骨肉瘤 MG-63 细胞增殖和凋亡的影响中国修复重建外科杂志2007-

部分，参考资料：^[7]

部分，参考资料：^{[8][9][10][7]}

2024年全国两会期间，张伟滨的提案聚焦护工的行业生态。表示应该为护工行业建立基本的薪酬制度，让护工享受符合国家规定的待遇，比如让节日坚持在岗的护工享受3倍工资等待遇。现在护工有活干就有钱，没活干就没钱，收入得不到保证；很多护工24小时连轴转，也没有正规的休息场所，这很容易导致疲劳工作；护工的福利靠病人家属自愿给付，私下给小费，这容易扰乱行业，在家属之间造成攀比。^[11]

2025年12月，针对骨肿瘤。张伟滨表示青少年是骨肉瘤的主要群体，他们的人生才刚刚开始，不能让转移成为终结符。将研究重点聚焦在“骨肉瘤干细胞外泌体诱导肺转移微环境”机制上。伟滨教授表示，骨肿瘤诊疗没有“终点”，但只要我们在技术上更精准、在协作上更高效、在研究上更深入，就能为患者多抢一点生机，多留一份希望，“这是骨科医生的责任，也是我们的初心。”^[5]

2026年3月6日，张伟滨表示，2026年全国两会，他会重点建议破解集采药品“低价低质”公众信任困境。^[12]

2022年9月，张伟滨获第四届“仁心医者·上海市杰出专科医师奖”。^[6]